 Home > Active Ingredient News > Endocrine System > Br J Pharmacol: Butyrate improves skeletal muscle atrophy in diabetic nephropathy by enhancing intestinal barrier function and FFA2-mediated PI3K/AKT/mTOR signaling pathway

Br J Pharmacol: Butyrate improves skeletal muscle atrophy in diabetic nephropathy by enhancing intestinal barrier function and FFA2-mediated PI3K/AKT/mTOR signaling pathway

 Last Update: 2021-10-20
 Source: Internet
 Author: User

Tags

hyaluronic acid interactions

zeta potential

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Protein energy consumption (PEW) is a state of catabolism caused by metabolic and nutritional disorders in a chronic disease state
.

Patients with DN and end-stage renal disease (ESRD) exhibit muscle atrophy, which leads to a worsening of the disease and an increase in morbidity

Metabolic and nutritional disorders lead to catabolism disorders.

Experimental method: We used metabonomics analysis to study the changes in serum butyrate levels in DN patients, explore the protective effect of butyrate on DN-induced muscle atrophy in db/db mice, and use C2C12 cells induced by HG/lps to study the effects of butyrate on Inhibition of muscle atrophy and its mechanism
.

Main results: We found that butyrate levels in DN patients decreased significantly
.

The addition of butyrate can significantly improve the intestinal barrier function

Figure 1 Metabolomics analysis
.

Metabolomics analysis found that according to the volcano map (A), there are 146 metabolites in the serum of DN patients and healthy people, and the heat map (B) shows significant up-regulation (38) and down-regulation (9) of potential biomarkers of metabolites.

Figure 1 Metabolomics analysis

Figure 2 Butyric acid is significantly related to DN and has a protective effect on renal function
.

Compared with healthy people, the butyric acid level of DN patients was significantly reduced (inpatients, n=15; butyric acid levels were also observed in db/db mice and the butyric acid treatment group (n=5) (C)

Figure 2 Butyric acid is significantly related to DN and has a protective effect on renal function

Figure 3 The process and mechanism of this research

Conclusion and significance: Butyrate, by enhancing the intestinal barrier function, activates the PI3K/AKT/mTOR pathway mediated by FFA2, and has a protective effect on DN-induced muscle atrophy
.

Butyrate enhances the intestinal barrier function and activates the PI3K/AKT/mTOR pathway mediated by FFA2, which has a protective effect on DN-induced muscle atrophy
.

Original source:

Tang G, Du Y, Guan H, Jia J,et al.

Butyrate ameliorate skeletal muscle atrophy in Diabetic Nephropathy via enhancing gut barrier function and FFA2-mediated PI3K/AKT/mTOR signals.
Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.